Recent News

• 03.18.2025 - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.18.2025 - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
• 11.27.2024 - Kronos Bio Announces CEO Transition and Reduction in Force
• 11.27.2024 - Kronos Bio Announces CEO Transition and Reduction in Force
• 11.14.2024 - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
• 11.14.2024 - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
• 11.13.2024 - Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
• 11.13.2024 - Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
• 11.13.2024 - Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
• 11.13.2024 - Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

Recent Filings

• 12.27.2024 - 8-K Current report
• 11.27.2024 - 8-K Current report
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2024 - EFFECT Notice of Effectiveness
• 11.13.2024 - EX-99.1 EX-99.1
• 11.13.2024 - 8-K Current report
• 11.13.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2024 - CORRESP Correspondence
• 11.12.2024 - UPLOAD SEC-generated letter
• 11.07.2024 - 8-K Current report